Skip to Main Content

Author Details

Alessandro Datti
University of Perugia
1991
97
38
PMIDPaper TitleJournal TitlePublished Year
36764576Academic drug discovery in an age of research abundance, and the curious case of chemical screens toward drug repositioning.Drug Discov Today2023
37511307Biochemical and Anthropometric Parameters for the Early Recognition of the Intrauterine Growth Restriction and Preterm Neonates at Risk of Impaired Neurodevelopment.Int J Mol Sci2023
37202533Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer.Commun Biol2023
35023164Hypophosphorylated pRb knock-in mice exhibit hallmarks of aging and vitamin C-preventable diabetes.EMBO J2022
35597023Retraction notice to "Coordinated involvement of cathepsins S, D and cystatin C in the commitment of hematopoietic stem cells to dendritic cells" [Int. J. Biochem. Cell Biol. 43 (2011) 775-783].Int J Biochem Cell Biol2022
35914530Systematic exploration of dynamic splicing networks reveals conserved multistage regulators of neurogenesis.Mol Cell2022
35913442Lesion Volume in a Bi- or Multivariate Prediction Model for the Management of PI-RADS v2.1 Score 3 Category Lesions.Turk J Urol2022
33234594An endogenous PI3K interactome promoting astrocyte-mediated neuroprotection identifies a novel association with RNA-binding protein ZC3H14.J Biol Chem2021
32295120Sorafenib as an Inhibitor of RUVBL2.Biomolecules2020
31864959Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.Oral Oncol2020
32094923A drug discovery platform to identify compounds that inhibit EGFR triple mutants.Nat Chem Biol2020
32062352Amplification of a calcium channel subunit CACNG4 increases breast cancer metastasis.EBioMedicine2020
32970704Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models.PLoS One2020
30548903Cell-based high-throughput screen for small molecule inhibitors of Bax translocation.J Cell Mol Med2019
31534157Selenium maintains cytosolic Ca<sup>2+ </sup>homeostasis and preserves germination rates of maize pollen under H<sub>2</sub>O<sub>2</sub>-induced oxidative stress.Sci Rep2019
29617654Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer.Cell Rep2018
29990484COX inhibitors and bone: A safer impact on osteoblasts by NO-releasing NSAIDs.Life Sci2018
29899842High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines.Oncotarget2018
30419054Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models.PLoS One2018
29069723Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer.Oncotarget2017
28157508Multilayered Control of Alternative Splicing Regulatory Networks by Transcription Factors.Mol Cell2017
26781438Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.Breast Cancer Res2016
26624983Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.Oncotarget2016
27612511Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells.Biol Open2016
27587383Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.Haematologica2016
27571409RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.J Clin Invest2016
27521426The RNF146 and tankyrase pathway maintains the junctional Crumbs complex through regulation of angiomotin.J Cell Sci2016
26942566High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor.Oncotarget2016
27006494Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.Clin Cancer Res2016
26952093PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.J Transl Med2016
26724904Identification of Drugs that Regulate Dermal Stem Cells and Enhance Skin Repair.Stem Cell Reports2016
25877919Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.Genes Dev2015
26077472Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death.Cancer Res2015
26115765Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.Mol Oncol2015
26109054Corrigendum: Myc and SAGA rewire an alternative splicing network during early somatic cell reprogramming.Genes Dev2015
25832785Select microtubule inhibitors increase lysosome acidity and promote lysosomal disruption in acute myeloid leukemia (AML) cells.Apoptosis2015
25165489A systematic approach to identify novel cancer drug targets using machine learning, inhibitor design and high-throughput screening.Genome Med2014
25330770Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.EMBO Mol Med2014
23129004Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity.J Cell Biochem2013
24104479A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.Mol Syst Biol2013
24265703RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs.PLoS One2013
23835716MicroRNA signature obtained from the comparison of aggressive with indolent non-Hodgkin lymphomas: potential prognostic value in mantle-cell lymphoma.J Clin Oncol2013
23974104High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.Cell Cycle2013
23439581Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients.Mult Scler2013
23202731Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.J Clin Invest2013
23319603High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer.Proc Natl Acad Sci U S A2013
23318959Inhibition of intracellular dipeptidyl peptidases 8 and 9 enhances parthenolide's anti-leukemic activity.Leukemia2013
22160482A small molecule screening strategy with validation on human leukemia stem cells uncovers the therapeutic efficacy of kinetin riboside.Blood2012
22829238Drug-mediated inhibition of Fli-1 for the treatment of leukemia.Blood Cancer J2012
22585861Essential gene profiles in breast, pancreatic, and ovarian cancer cells.Cancer Discov2012
  • 1 - 50 of 97

Recommended Authors

The Scripps Research Institute
Career Start Year 2003
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 16
Institute of Molecular and Cell Biology
Career Start Year 2000
Number of shared co-authors 1
Chengdu Medical College
Career Start Year 1999
Number of shared co-authors 0
Kaohsiung Medical University
Career Start Year 1998
Number of shared co-authors 0
University of Alabama at Birmingham
Career Start Year 1997
Number of shared co-authors 0
Institut Curie, PSL Research University
Career Start Year 1996
Number of shared co-authors 0
Yale University
Career Start Year 1996
Number of shared co-authors 1
The University of Melbourne, Peter MacCallum Cancer Centre
Career Start Year 1996
Number of shared co-authors 1
Sirna Therapeutics a former subsidiary of Merck & Co., Inc.
Career Start Year 1994
Number of shared co-authors 0
Caryl and Israel Englander Institute for Precision Medicine.
Career Start Year 1993
Number of shared co-authors 1
Mayo Clinic
Career Start Year 1993
Number of shared co-authors 0
Massey Cancer Center, Virginia Commonwealth University
Career Start Year 1992
Number of shared co-authors 0
College of Animal Medicine, Xinjiang Agricultural University
Career Start Year 1992
Number of shared co-authors 3
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 4
Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield
Career Start Year 1991
Number of shared co-authors 0
St. George's University Medical School
Career Start Year 1990
Number of shared co-authors 0
Medical University of South Carolina
Career Start Year 1989
Number of shared co-authors 3
Amsterdam University Medical Center
Career Start Year 1989
Number of shared co-authors 0
Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina de Sao Paulo
Career Start Year 1989
Number of shared co-authors 2
University of Cape Town
Career Start Year 1988
Number of shared co-authors 0
Institute of Pharmacy and Molecular Biotechnology, Heidelberg University
Career Start Year 1987
Number of shared co-authors 0
Vrije Universiteit Amsterdam (VU)
Career Start Year 1987
Number of shared co-authors 0
Moffitt Cancer Center
Career Start Year 1986
Number of shared co-authors 0
Broad Institute
Career Start Year 1985
Number of shared co-authors 2
Hoag Memorial Hospital Presbyterian
Career Start Year 1983
Number of shared co-authors 2
Child and Family Research Institute, University of British Columbia
Career Start Year 1979
Number of shared co-authors 0
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 13
Oregon Health and Science University
Career Start Year 1973
Number of shared co-authors 0
The University of Texas MD Anderson Cancer Center
Career Start Year 1968
Number of shared co-authors 3

Collaborators

Lunenfeld-Tanenbaum Research Institute Mount Sinai Hospital
Co-authored papers 34
Princess Margaret Cancer Centre
Co-authored papers 20
Princess Margaret Cancer Centre
Co-authored papers 15
College of Medicine, University of Saskatchewan
Co-authored papers 14
Princess Margaret Cancer Centre
Co-authored papers 13
University of Toronto
Co-authored papers 9
Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University Avenue R988
Co-authored papers 9
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 7
University of Toronto
Co-authored papers 7
University of California los angeles
Co-authored papers 7
University of Western Ontario
Co-authored papers 5
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 5
University of Western Ontario
Co-authored papers 5
Schulich School of Medicine & Dentistry, Western University
Co-authored papers 5
School of Public Policy at the University of Calgary
Co-authored papers 5
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 5
University of Western Ontario
Co-authored papers 5
College of Medicine, University of Saskatchewan
Co-authored papers 5
Schulich School of Medicine & Dentistry, Western University, Victoria Hospital
Co-authored papers 5
Schulich School of Medicine and Dentistry, Western University
Co-authored papers 5
University of Toronto
Co-authored papers 4
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 4
University of Toronto
Co-authored papers 4
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 4
Western University
Co-authored papers 4
University of Toronto
Co-authored papers 4
University of Toronto
Co-authored papers 4
Ontario Institute for Cancer Research, University Avenue
Co-authored papers 4
Hangzhou City University
Co-authored papers 4
Lunenfeld-Tanenbaum Research Institute
Co-authored papers 4